Premium accounts now available! Sign up and create a premium account. Read more Close

Advertisement

Image

A Cross-kingdom Effector Modulates EDS1-dependent TIR-NLR-mediated Plant Immunity

Preprint Created on 22 May 2026 bioRxiv

In the ongoing battle between plants and pathogens, successful pathogens promote colonization by evolving new effectors that manipulate counteractive host responses, such as intracellular nucleotide-binding leucine-rich repeat (NLR)-triggered immunity. Here, we identify a secreted effector, PbSTMI, from the unique intracellular protist Plasmodiophora brassicae, that is conserved across divergent plant pathogens and broadly suppresses ENHANCED DISEASE SUSCEPTIBILITY 1 (EDS1)-dependent plant immunity. PbSTMI directly binds EDS1 and promotes its proteasome-mediated degradation, thereby diminishing downstream EDS1 oligomerization required for resistance. PbSTMI overexpression suppresses toll/interleukin-1 receptor (TIR) domain-containing NLR (TIR-NLR)-driven autoimmunity in Arabidopsis and further attenuates salicylic acid-mediated signaling in the autoimmune background. It blocks flg22-induced accumulation of EDS1 and regulates SA-mediated PAMP-triggered immunity (PTI) responses. Oligomerization among PbSTMI and its paralogs suggests coordinated immune suppression during different stages of P. brassicae infection and clubroot disease progression. PbSTMI suppression of EDS1-dependent TIR-NLR-mediated pathways increases susceptibility to a broad range of phytopathogens, including the biotrophs P. brassicae and Erysiphe cichoracearum and the hemibiotrophic Colletotrichum higginsianum. Together, these findings reveal a conserved pathogen strategy that disarms a central immune hub, tipping the balance of the plant-pathogen arms race decisively in favor of the pathogen.

Hossain, M., Wei, Y., Bonham-Smith, P. C., Todd, C. D.

Advertisement

Stats

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 9
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement